| Q34097425 | A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. |
| Q50617169 | Advances in PET/MR instrumentation and image reconstruction. |
| Q40780999 | Anal cancer FDG-PET standard uptake value: correlation with tumor characteristics, treatment response and survival |
| Q91955544 | Anal cancer chemoradiotherapy outcome prediction using 18F-fluorodeoxyglucose positron emission tomography and clinicopathological factors |
| Q35213015 | Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy |
| Q57788887 | Does baseline [18F] FDG-PET/CT correlate with tumor staging, response after neoadjuvant chemoradiotherapy, and prognosis in patients with rectal cancer? |
| Q35096160 | FDG volumetric parameters and survival outcomes after definitive chemoradiotherapy in patients with recurrent head and neck squamous cell carcinoma |
| Q92457848 | FDG-PET parameters predict for recurrence in anal cancer - results from a prospective, multicentre clinical trial |
| Q52728695 | High GSTP1 inhibits cell proliferation by reducing Akt phosphorylation and is associated with a better prognosis in hepatocellular carcinoma. |
| Q42097286 | Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs) |
| Q99583935 | Incidental anal 18fluorodeoxyglucose uptake: Should we further examine the patient? |
| Q35109012 | Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma |
| Q93090514 | Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT |
| Q40630184 | Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer |
| Q90194960 | Prognostic value of 18F-FDG PET /CT metabolic parameters in patients with locally advanced pancreatic Cancer treated with stereotactic body radiation therapy |
| Q26824040 | Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers |
| Q38344332 | The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis. |
| Q91668881 | The effect of different segmentation methods on primary tumour metabolic volume assessed in 18F-FDG-PET/CT in patients with cervical cancer, for radiotherapy planning |
| Q97542012 | Treatment outcome after radiochemotherapy in anal cancer patients staged with 18F-FDG-PET-CT |